Data / Drug companies / Mylan Institutional LLC
Mylan Institutional LLC: 137 products in the FDA NDC directory, labeler code 67457
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Mylan Institutional LLC (labeler code 67457) lists 137 products in the FDA National Drug Code Directory, covering 70 finished drugs by generic name. By type: 137 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.
The request: Watch Mylan Institutional LLC (FDA labeler code 67457): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67457
- Products in commercial distribution
- 137
- Packages
- 142
- Finished drugs by generic name
- 70
- Prescription products
- 137
- Over the counter products
- 0
- Controlled substance products
- Schedule II 4
- Flagged as original packager
- 130 of 130 products that carry the flag
- Started marketing in the last 12 months
- 6
- Products with a marketing end date set
- 4
- Earliest marketing start
- April 4, 1978
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 111 | 81% |
| New drug applications (NDA) | 18 | 13.1% |
| Authorized generics (NDA) | 4 | 2.9% |
| Other unapproved drugs | 2 | 1.5% |
| Biologics (BLA) | 2 | 1.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 137 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 68 | 49.6% |
| Injection, powder, lyophilized, for solution | 26 | 19% |
| Injection | 20 | 14.6% |
| Injection, solution, concentrate | 7 | 5.1% |
| Kit | 5 | 3.6% |
| Injection, powder, lyophilized, for suspension | 5 | 3.6% |
| Injection, suspension | 4 | 2.9% |
| Solution | 1 | 0.7% |
| Irrigant | 1 | 0.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sugammadex | 67457-970 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Sugammadex | 67457-969 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Ferric Carboxymaltose | 67457-797 | Injection, solution | Generic drugs (ANDA) | July 1, 2026 |
| Octreotide acetate | 67457-762 | Kit | Generic drugs (ANDA) | January 28, 2026 |
| Octreotide acetate | 67457-759 | Kit | Generic drugs (ANDA) | January 28, 2026 |
| Octreotide acetate | 67457-756 | Kit | Generic drugs (ANDA) | January 28, 2026 |
| Paclitaxel | 67457-937 | Injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | October 9, 2025 |
| Iron Sucrose | 67457-957 | Injection, solution | Generic drugs (ANDA) | August 8, 2025 |
| Iron Sucrose | 67457-639 | Injection, solution | Generic drugs (ANDA) | August 8, 2025 |
| Iron Sucrose | 67457-638 | Injection, solution | Generic drugs (ANDA) | August 8, 2025 |
| Amphotericin B liposome | 67457-926 | Injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | August 6, 2025 |
| Epoprostenol | 67457-588 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 25, 2024 |
| Epoprostenol | 67457-587 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 25, 2024 |
| Posaconazole | 67457-665 | Solution | Generic drugs (ANDA) | March 22, 2024 |
| Ropivacaine hydrochloride | 67457-799 | Injection, solution | Generic drugs (ANDA) | March 18, 2024 |
| Ropivacaine hydrochloride | 67457-798 | Injection, solution | Generic drugs (ANDA) | March 18, 2024 |
| Daptomycin | 67457-941 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 27, 2023 |
| Triamcinolone acetonide | 67457-623 | Injection, suspension | Generic drugs (ANDA) | May 8, 2023 |
| Triamcinolone acetonide | 67457-622 | Injection, suspension | Generic drugs (ANDA) | May 8, 2023 |
| Triamcinolone acetonide | 67457-621 | Injection, suspension | Generic drugs (ANDA) | May 8, 2023 |
| Naloxone Hydrochloride | 67457-992 | Injection, solution | Generic drugs (ANDA) | December 2, 2022 |
| Mycophenolate Mofetil | 67457-386 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 26, 2021 |
| Acetaminophen | 67457-940 | Injection, solution | Generic drugs (ANDA) | December 7, 2020 |
| Dexmedetomidine hydrochloride | 67457-925 | Injection, solution | Generic drugs (ANDA) | November 13, 2020 |
| Dexmedetomidine hydrochloride | 67457-924 | Injection, solution | Generic drugs (ANDA) | November 13, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.